News room

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Chairman of the board of directors in Egetis Therapeutics acquires shares

May 24, 2021

Stockholm, Sweden, May 24, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Dr Thomas Lönngren, Chairman of the Board, has via PharmaExec Consulting AB acquired 100,000 shares in the company.

Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Dr Thomas Lönngren, Chairman of the Board, has via PharmaExec Consulting AB acquired 100,000 shares in the company.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com